iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

iRhythm (NASDAQ:IRTC) provided preliminary Q4 2025 highlights and a business update at the 44th Annual J.P.

Rhea-AI Summary

iRhythm (NASDAQ:IRTC) provided preliminary Q4 2025 highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. The company expects full‑year 2025 revenue to exceed the high end of prior guidance of $740 million, driven by record revenue unit volume in Q4 2025. For full‑year 2026, iRhythm projects revenue of $870–$880 million (approximately 17%–18% YoY) and an adjusted EBITDA margin of ~11.5%–12.5%. Management cited clinical evidence from >1.4 million patients supporting Zio long‑term continuous monitoring and noted free cash flow positivity in 2025. Management presented on Jan 12, 2026 at 8:15 AM PT; a live and archived webcast is available on the company investor site.

Positive

• Full‑year 2025 revenue expected to exceed $740M guidance high end
• 2026 revenue guidance of $870–$880M (~17%–18% YoY growth)
• Adjusted EBITDA margin guidance of ~11.5%–12.5% for 2026
• Achieved free cash flow positivity for the first time in company history
• Clinical evidence from >1.4 million patients supporting Zio LTCM performance

Argus Jan 12 session

-5.82% close to close Open Argus

Details

News Market Reaction – IRTC

On Jan 12, the day this news came out, IRTC closed 5.82% below the previous close.

Data tracked by StockTitan Argus for the Jan 12 session.

Market Context

On Jan 12, the day this news came out, the stock closed 5.8% below the previous close. The decline r...

Analysis

On Jan 12, the day this news came out, the stock closed 5.8% below the previous close. The decline reflects a divergence between strong fundamentals and near-term trading. Management expects 2026 revenue of $870M–$880M with adjusted EBITDA margins of 11.5%–12.5%, building on over 25% 2025 revenue growth and large real‑world datasets. Historically, one prior earnings beat also coincided with a mild pullback, suggesting that expectations and positioning can overshadow positive updates and may contribute to volatility after guidance changes.

Key Figures

FY2025 prior guidance high end: $740M FY2026 revenue outlook: $870M–$880M FY2026 adj. EBITDA margin: 11.5%–12.5% +3 more

FY2025 prior guidance high end

$740M

Previously stated 2025 revenue guidance high end from October 2025

FY2026 revenue outlook

$870M–$880M

Preliminary 2026 revenue expectation; 17%–18% YoY growth

FY2026 adj. EBITDA margin

11.5%–12.5%

Preliminary adjusted EBITDA margin guidance for full year 2026

Real-world patients

1.4 million+

Patients included in real-world evidence supporting Zio LTCM

2025 revenue growth

25%+ YoY

Management commentary on over 25% year-over-year revenue growth in 2025

Conference presentation time

8:15 a.m. PT / 11:15 a.m. ET

Scheduled J.P. Morgan Healthcare Conference presentation on Jan 12, 2026

Historical Context

5 past events · Latest: Dec 29

5 events

1. Dec 29

   Conference participation

   24h Move

   -0.0%

   Announcement of planned presentation at J.P. Morgan Healthcare Conference.

2. Nov 21

   Clinical data update

   24h Move

   +4.8%

   APHRS 2025 data showing consistent Zio LTCM performance in Asian populations.

3. Nov 11

   Clinical publications

   24h Move

   +0.0%

   Heart Rhythm and AHA 2025 results highlighting advantages of long-term monitoring.

4. Nov 04

   Investor conferences

   24h Move

   -0.3%

   Schedule of multiple investor conference presentations released.

5. Oct 30

   Earnings results

   24h Move

   -0.6%

   Strong Q3 2025 growth and raised 2025 guidance accompanied by a small share decline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

adjusted EBITDA margin, real-world evidence, long-term continuous monitoring (LTCM), mobile cardiac telemetry, +2 more

6 terms

adjusted EBITDA margin financial

"and anticipate adjusted EBITDA margin of approximately 11.5% to 12.5%"

Adjusted EBITDA margin shows how much profit a company makes from its core operations, expressed as a percentage of its total revenue, after removing certain one-time or unusual expenses and income. It helps investors understand the company's true earning ability from regular business activities, making it easier to compare performance over time or with other companies. Think of it as measuring the efficiency of a business in turning sales into profits, excluding irregular adjustments.

real-world evidence medical

"Recently-presented real-world evidence from over 1.4 million patients reinforces Zio"

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

long-term continuous monitoring (LTCM) medical

"reinforces Zio long-term continuous monitoring (LTCM) clinical superiority"

Long-term continuous monitoring (LTCM) is the ongoing collection of health or device performance data from patients or medical devices over months or years, often using wearable sensors or implanted systems. For investors, LTCM matters because it demonstrates real-world safety, effectiveness and product durability, can unlock regulatory approvals or reimbursements, and may create steady revenue streams or lower liability — like a car’s black box that proves how well it actually performs over time.

mobile cardiac telemetry medical

"including deepening penetration in primary care... momentum within mobile cardiac telemetry"

A wearable system that continuously records a person’s heart rhythm and sends that data in real time to clinicians or monitoring centers for immediate analysis and alerting. Think of it as a live security camera for the heart that can catch irregular beats or dangerous events that short clinic tests might miss. Investors care because it can drive recurring service revenue, affect reimbursement and adoption trends, and reduce costly hospital visits by enabling earlier detection and remote care.

obstructive sleep apnea medical

"expansion into adjacent markets such as obstructive sleep apnea"

Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.

AI-powered risk stratification technical

"through AI-powered risk stratification partnerships, momentum within mobile cardiac"

AI-powered risk stratification uses artificial intelligence to sort people, assets, or situations into buckets based on the likelihood they will produce a particular outcome, such as default, disease progression, or fraud. Like a smart traffic light that directs vehicles by risk, it helps investors decide where to deploy capital, set prices or reserves, and prioritize oversight by turning complex data into faster, more granular risk judgments — though results depend on the quality of the input data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 44^th Annual J.P. Morgan Healthcare Conference.

Recent Operational Highlights and Financial Outlook

• Anticipate full year 2025 revenue to exceed high end of previously stated guidance range of $740 million provided in October 2025, driven by record revenue unit volume during the fourth quarter 2025
• For full year 2026, expect revenue of approximately $870 million to $880 million, or approximately 17% to 18% year-over-year growth, and anticipate adjusted EBITDA margin of approximately 11.5% to 12.5%
• Recently-presented real-world evidence from over 1.4 million patients reinforces Zio long-term continuous monitoring (LTCM) clinical superiority, with APHRS 2025 data demonstrating consistent performance in Asian populations¹, a Heart Rhythm publication confirming short-term monitoring misses actionable arrhythmias², and AHA 2025 data validating successful at-home self-application and earlier detection in at-risk populations^3-6
  
  

"2025 has been a transformative year for iRhythm, with strong execution against our aspiration to drive best-in-class quality systems, record commercial volumes, over 25% year-over-year revenue growth, and achieving free cash flow positivity for the first time in company history,” said Quentin Blackford, iRhythm’s President and CEO. “Our comprehensive clinical evidence program – including AVALON⁷ and CAMELOT⁸ publications – continues to reinforce Zio LTCM's clinical superiority in support of addressable market expansion across additional populations and care settings. As we enter 2026, we're well-positioned to accelerate our leadership with multiple growth catalysts ahead, including deepening penetration in primary care and population health through AI-powered risk stratification partnerships, momentum within mobile cardiac telemetry, expansion into adjacent markets such as obstructive sleep apnea, and continued international execution. With our proven ability to scale efficiently, we're confident we can deliver sustainable, profitable growth while transforming cardiac care for millions of patients worldwide."

Webcast and Conference Presentation Information

At the upcoming 44^th Annual J.P. Morgan Healthcare Conference, iRhythm’s management is scheduled to present on Monday, January 12, 2026, at 8:15 a.m. Pacific Time/11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the Events and Presentations section of the company’s investor website at investors.irhythmtech.com.

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. To learn more about iRhythm, including its portfolio of Zio products and services, please visit irhythmtech.com.

Use of Non-GAAP Financial Measures

We refer to certain financial measures that are not recognized under U.S. generally accepted accounting principles (GAAP) in this press release and management’s presentation materials, including adjusted EBITDA, adjusted net loss, adjusted net loss per share, adjusted operating expenses, and free cash flow. We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. See the schedules attached to management’s presentation materials for additional information and reconciliations of such non-GAAP financial measures. We have not reconciled our adjusted operating expenses and adjusted EBITDA margin estimates for full year 2026 because certain items that impact these figures are uncertain or out of our control and cannot be reasonably predicted. Accordingly, a reconciliation of adjusted EBITDA estimates is not available without unreasonable effort.

Adjusted EBITDA excludes non-cash operating charges for stock-based compensation expense, changes in fair value of strategic investments, impairment and restructuring charges, business transformation costs, certain intellectual property litigation expenses and settlements, and loss on extinguishment of debt. Business transformation costs include costs associated with professional services, employee termination and relocation, third-party merger and acquisition, integration, and other costs to augment and restructure the organization, inclusive of both outsourced and offshore resources.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance. In particular, these statements include statements regarding financial guidance, market opportunity, ability to penetrate the market, anticipated productivity and quality improvements, and expectations for growth. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including those in iRhythm’s most recent filings on Form 10-K, Form 10-Q and other SEC filings, all of which are available on iRhythm’s website. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Contact
Stephanie Zhadkevich
investors@irhythmtech.com

Media Contact
Kassandra Perry
irhythm@highwirepr.com

1. Kawata H et al. Clinical Performance of a Long-Term Continuous ECG Monitoring System in Asian and Non-Asian Patients: A Large-Scale Real-World Analysis of Over 400,000 Patients. Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions, November 13, 2025; Yokohama, Japan.
2. Battisti AJ, et al. Relationship of Symptom Frequency and Symptom-Rhythm Correlation to Arrhythmia Type and Time to Detection: Insights from Ambulatory ECG Monitoring in Over 1 Million Patients. Heart Rhythm. 2025 Nov 6:S1547-5271(25)03049-8. doi: 10.1016/j.hrthm.2025.11.007. Epub ahead of print.
3. Ashburner JM et al. Compliance, ECG Quality, and Engagement With a Smartphone App in Patients With In-Clinic Compared With Home-Based, Self-Applied Long-Term Continuous ECG Patch Monitors. American Heart Association Scientific Sessions, November 10, 2025; New Orleans, Louisiana.
4. Russo P et al. “Onset of Arrhythmias in the CKM Continuum: Real-World Insights From a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.
5. Russo P et al. “CKD and CKM Syndrome: Accelerated Progression to Arrhythmias in a National Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.
6. Russo P et al. “Arrhythmias as Early Predictors of Chronic Kidney Disease: Real-World Evidence From a National Cardio-Kidney-Metabolic Cohort.” American Heart Association Scientific Sessions, 2025; New Orleans, Louisiana.
7. Russo et al. Assessment of variation in ambulatory cardiac monitoring among commercially insured patients. Am J Manag Care. August 13, 2025.
8. Reynolds MR, et al. Comparative effectiveness and healthcare utilization for ambulatory cardiac monitoring strategies in Medicare beneficiaries. Am Heart J. 2024 Mar;269:25-34

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What revenue did iRhythm (IRTC) report for full‑year 2025?

iRhythm expects full‑year 2025 revenue to exceed the prior guidance high end of $740 million.

What is iRhythm's 2026 revenue and margin guidance (IRTC)?

The company guided 2026 revenue of $870–$880 million (≈17%–18% YoY) and adjusted EBITDA margin of ~11.5%–12.5%.

When and where did iRhythm present at the J.P. Morgan Healthcare Conference?

Management presented on January 12, 2026 at 8:15 AM PT / 11:15 AM ET; a live and archived webcast is on the company's investor website.

Did iRhythm report any cash flow milestones in the update?

Yes; the company reported achieving free cash flow positivity for the first time in company history in 2025.

What clinical evidence did iRhythm cite to support Zio performance?

iRhythm cited real‑world evidence from over 1.4 million patients and recent presentations/publications demonstrating Zio LTCM clinical performance and at‑home self‑application validation.